{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T16:58:06Z","timestamp":1791305886736,"version":"4.3.1"},"reference-count":48,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T00:00:00Z","timestamp":1791244800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T00:00:00Z","timestamp":1791244800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Neurol Ther"],"DOI":"10.1007\/s40120-026-01045-4","type":"journal-article","created":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T16:48:13Z","timestamp":1791305293000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Triple Preventive Therapy with OnabotulinumtoxinA, Fremanezumab, and Atogepant in Treatment-Resistant Chronic Migraine: A 52-Week Pilot Case Series (TRIPLE Cohort)"],"prefix":"10.1007","author":[{"given":"Marina","family":"Romozzi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luigi Francesco","family":"Iannone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Russo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ian","family":"Finkelstein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dineo","family":"Seabi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adam","family":"Ahlden","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne Hege","family":"Aamodt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catello","family":"Vollono","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paolo","family":"Calabresi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edoardo","family":"Caronna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patricia","family":"Pozo-Rosich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erling Andreas","family":"Tronvik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-4372-5874","authenticated-orcid":false,"given":"Christina","family":"Sundal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,10,6]]},"reference":[{"issue":"19","key":"1045_CR1","doi-asserted-by":"publisher","first-page":"1866","DOI":"10.1056\/NEJMra1915327","volume":"383","author":"M Ashina","year":"2020","unstructured":"Ashina M. Migraine. N Engl J Med. 2020;383(19):1866\u201376.","journal-title":"N Engl J Med"},{"key":"1045_CR2","doi-asserted-by":"crossref","unstructured":"Hus\u2298y AK, et al. Global, regional, and national burden of headache disorders, 1990\u20132023: a systematic analysis for the Global Burden of Disease Study 2023. Lancet Neurol. 2025;24(12): 1005\u20131015","DOI":"10.1016\/S1474-4422(25)00402-8"},{"issue":"9","key":"1045_CR3","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1038\/s41582-024-01002-5","volume":"20","author":"P Pozo-Rosich","year":"2024","unstructured":"Pozo-Rosich P, et al. Insights from 25 years of onabotulinumtoxinA in migraine - mechanisms and management. Nat Rev Neurol. 2024;20(9):555\u201368.","journal-title":"Nat Rev Neurol"},{"issue":"10483","key":"1045_CR4","doi-asserted-by":"publisher","first-page":"1014","DOI":"10.1016\/S0140-6736(25)00109-6","volume":"405","author":"J Versijpt","year":"2025","unstructured":"Versijpt J, et al. Calcitonin gene-related peptide-targeted therapy in migraine: current role and future perspectives. Lancet. 2025;405(10483):1014\u201326.","journal-title":"Lancet"},{"issue":"1","key":"1045_CR5","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1186\/s10194-024-01925-w","volume":"25","author":"L Pellesi","year":"2024","unstructured":"Pellesi L, et al. Combining treatments for migraine prophylaxis: the state-of-the-art. J Headache Pain. 2024;25(1):214.","journal-title":"J Headache Pain"},{"issue":"7","key":"1045_CR6","doi-asserted-by":"publisher","first-page":"3654","DOI":"10.1007\/s00415-023-11706-1","volume":"270","author":"F Puledda","year":"2023","unstructured":"Puledda F, et al. Migraine: from pathophysiology to treatment. J Neurol. 2023;270(7):3654\u201366.","journal-title":"J Neurol"},{"issue":"7","key":"1045_CR7","doi-asserted-by":"publisher","first-page":"1628","DOI":"10.1111\/head.70114","volume":"66","author":"LF Iannone","year":"2026","unstructured":"Iannone LF, et al. The pharmacology of gepants in migraine: a scoping review on mechanisms, clinical applications, and combination strategies. Headache. 2026;66(7):1628\u201343.","journal-title":"Headache"},{"issue":"10","key":"1045_CR8","first-page":"927","volume":"95","author":"E Caronna","year":"2024","unstructured":"Caronna E, et al. Redefining migraine prevention: early treatment with anti-CGRP monoclonal antibodies enhances response in the real world. J Neurol Neurosurg Psychiatry. 2024;95(10):927\u201337.","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"4","key":"1045_CR9","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000214659","volume":"106","author":"E Caronna","year":"2026","unstructured":"Caronna E, et al. Long-term effectiveness and persistence factors of anti-CGRP monoclonal antibodies in migraine: 2-year results from the EUREkA cohort. Neurology. 2026;106(4):e214659.","journal-title":"Neurology"},{"issue":"11","key":"1045_CR10","doi-asserted-by":"publisher","DOI":"10.1177\/03331024241273968","volume":"44","author":"A Burgalassi","year":"2024","unstructured":"Burgalassi A, et al. Outcomes, unmet needs, and challenges in the management of patients who withdraw from anti-CGRP monoclonal antibodies: a prospective cohort study. Cephalalgia. 2024;44(11):03331024241273968.","journal-title":"Cephalalgia"},{"issue":"7","key":"1045_CR11","doi-asserted-by":"publisher","first-page":"1937","DOI":"10.1111\/ene.15816","volume":"30","author":"M Torres-Ferrus","year":"2023","unstructured":"Torres-Ferrus M, et al. Patterns of response to anti-calcitonin gene-related peptide monoclonal antibodies during first 6 months of treatment in resistant migraine patients: impact on outcome. Eur J Neurol. 2023;30(7):1937\u201344.","journal-title":"Eur J Neurol"},{"issue":"5","key":"1045_CR12","doi-asserted-by":"publisher","first-page":"1533","DOI":"10.1007\/s40120-023-00529-x","volume":"12","author":"AM Blumenfeld","year":"2023","unstructured":"Blumenfeld AM, et al. Multimodal migraine management and the pursuit of migraine freedom: a narrative review. Neurol Ther. 2023;12(5):1533\u201351.","journal-title":"Neurol Ther"},{"issue":"2","key":"1045_CR13","doi-asserted-by":"publisher","first-page":"033310242513206","DOI":"10.1177\/03331024251320608","volume":"45","author":"S Sacco","year":"2025","unstructured":"Sacco S, et al. Setting higher standards for migraine prevention: A position statement of the International Headache Society. Cephalalgia. 2025;45(2):03331024251320608.","journal-title":"Cephalalgia"},{"issue":"1","key":"1045_CR14","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/15360288.2020.1829249","volume":"35","author":"M Armanious","year":"2021","unstructured":"Armanious M, et al. Erenumab and OnabotulinumtoxinA combination therapy for the prevention of intractable chronic migraine without aura: a retrospective analysis. J Pain Palliat Care Pharmacother. 2021;35(1):1\u20136.","journal-title":"J Pain Palliat Care Pharmacother"},{"issue":"2","key":"1045_CR15","doi-asserted-by":"publisher","first-page":"809","DOI":"10.1007\/s40122-021-00264-x","volume":"10","author":"AM Blumenfeld","year":"2021","unstructured":"Blumenfeld AM, et al. Real-world evidence for control of chronic migraine patients receiving CGRP monoclonal antibody therapy added to OnabotulinumtoxinA: a retrospective chart review. Pain Ther. 2021;10(2):809\u201326.","journal-title":"Pain Ther"},{"issue":"6","key":"1045_CR16","doi-asserted-by":"publisher","first-page":"1571","DOI":"10.1007\/s40122-024-00649-8","volume":"13","author":"AM Blumenfeld","year":"2024","unstructured":"Blumenfeld AM, et al. Real-world evidence of the safety and effectiveness of Atogepant added to OnabotulinumtoxinA for the preventive treatment of chronic migraine: a retrospective chart review. Pain Ther. 2024;13(6):1571\u201387.","journal-title":"Pain Ther"},{"issue":"12","key":"1045_CR17","doi-asserted-by":"publisher","DOI":"10.1177\/03331024251398011","volume":"45","author":"LF Iannone","year":"2025","unstructured":"Iannone LF, et al. Combination preventive therapy with onabotulinumtoxinA and atogepant for chronic migraine: a 24-week, prospective, real-world evaluation (SYNERGY study). Cephalalgia. 2025;45(12):3331024251398011.","journal-title":"Cephalalgia"},{"issue":"1","key":"1045_CR18","doi-asserted-by":"publisher","DOI":"10.1186\/s10194-024-01783-6","volume":"25","author":"RB Lipton","year":"2024","unstructured":"Lipton RB, et al. Sustained response to atogepant in episodic migraine: post hoc analyses of a 12-week randomized trial and a 52-week long-term safety trial. J Headache Pain. 2024;25(1):83.","journal-title":"J Headache Pain"},{"key":"1045_CR19","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2021.788159","volume":"12","author":"L Mechtler","year":"2021","unstructured":"Mechtler L, et al. Real-world evidence for the safety and efficacy of CGRP monoclonal antibody therapy added to OnabotulinumtoxinA treatment for migraine prevention in adult patients with chronic migraine. Front Neurol. 2021;12:788159.","journal-title":"Front Neurol"},{"issue":"4","key":"1045_CR20","doi-asserted-by":"publisher","DOI":"10.1177\/03331024261429118","volume":"46","author":"J Rothrock","year":"2026","unstructured":"Rothrock J, et al. Safety, tolerability, and efficacy of atogepant added to OnabotulinumtoxinA for the preventive treatment of chronic migraine: a phase 3, multicenter, 24-week, open-label study. Cephalalgia. 2026;46(4):03331024261429118.","journal-title":"Cephalalgia"},{"key":"1045_CR21","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2021.656294","volume":"12","author":"M Silvestro","year":"2021","unstructured":"Silvestro M, et al. Additive interaction between Onabotulinumtoxin-A and Erenumab in patients with refractory migraine. Front Neurol. 2021;12:656294.","journal-title":"Front Neurol"},{"issue":"1","key":"1045_CR22","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1111\/head.14244","volume":"62","author":"J Ailani","year":"2022","unstructured":"Ailani J, Blumenfeld AM. Combination CGRP monoclonal antibody and OnabotulinumtoxinA treatment for preventive treatment in chronic migraine. Headache. 2022;62(1):106\u20138.","journal-title":"Headache"},{"issue":"2","key":"1045_CR23","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1007\/s40120-024-00586-w","volume":"13","author":"T Alsaadi","year":"2024","unstructured":"Alsaadi T, et al. Safety and tolerability of combining CGRP monoclonal antibodies with gepants in patients with migraine: a retrospective study. Neurol Ther. 2024;13(2):465\u201373.","journal-title":"Neurol Ther"},{"issue":"8","key":"1045_CR24","doi-asserted-by":"publisher","first-page":"1734","DOI":"10.1111\/head.13930","volume":"60","author":"G Berman","year":"2020","unstructured":"Berman G, et al. Safety of rimegepant, an oral CGRP receptor antagonist, plus CGRP monoclonal antibodies for migraine. Headache. 2020;60(8):1734\u201342.","journal-title":"Headache"},{"issue":"7","key":"1045_CR25","doi-asserted-by":"publisher","first-page":"1180","DOI":"10.1111\/head.14954","volume":"65","author":"G Berman","year":"2025","unstructured":"Berman G, et al. Long-term safety and tolerability of zavegepant 10-mg nasal spray with concomitant use of anti-calcitonin gene-related peptide monoclonal antibodies or other select preventive migraine medications: results from a phase 2\/3 open-label study. Headache. 2025;65(7):1180\u20139.","journal-title":"Headache"},{"issue":"1","key":"1045_CR26","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1007\/s40120-023-00556-8","volume":"13","author":"RB Lipton","year":"2024","unstructured":"Lipton RB, et al. Real-world use of ubrogepant as acute treatment for migraine with an anti-calcitonin gene-related peptide monoclonal antibody: results from COURAGE. Neurol Ther. 2024;13(1):69\u201383.","journal-title":"Neurol Ther"},{"issue":"4","key":"1045_CR27","doi-asserted-by":"publisher","first-page":"642","DOI":"10.1111\/head.14095","volume":"61","author":"A Jakate","year":"2021","unstructured":"Jakate A, et al. Pharmacokinetics and safety of ubrogepant when coadministered with calcitonin gene-related peptide-targeted monoclonal antibody migraine preventives in participants with migraine: a randomized phase 1b drug-drug interaction study. Headache. 2021;61(4):642\u201352.","journal-title":"Headache"},{"issue":"1","key":"1045_CR28","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1186\/s10194-020-01130-5","volume":"21","author":"S Sacco","year":"2020","unstructured":"Sacco S, et al. European headache federation consensus on the definition of resistant and refractory migraine: developed with the endorsement of the European Migraine & Headache Alliance (EMHA). J Headache Pain. 2020;21(1):76.","journal-title":"J Headache Pain"},{"key":"1045_CR29","doi-asserted-by":"crossref","unstructured":"Bjelland I, et al. The validity of the hospital anxiety and depression scale. An updated literature review. J Psychosom Res. 2002; 52(2): 69\u201377.","DOI":"10.1016\/S0022-3999(01)00296-3"},{"issue":"1","key":"1045_CR30","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1016\/j.jmpt.2003.11.003","volume":"27","author":"H Hurst","year":"2004","unstructured":"Hurst H, Bolton J. Assessing the clinical significance of change scores recorded on subjective outcome measures. J Manipulative Physiol Ther. 2004;27(1):26\u201335.","journal-title":"J Manipulative Physiol Ther"},{"issue":"1","key":"1045_CR31","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1177\/03331024211042385","volume":"42","author":"TJ Schwedt","year":"2022","unstructured":"Schwedt TJ, et al. Time course of efficacy of atogepant for the preventive treatment of migraine: results from the randomized, double-blind ADVANCE trial. Cephalalgia. 2022;42(1):3\u201311.","journal-title":"Cephalalgia"},{"issue":"1","key":"1045_CR32","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1186\/s10194-022-01393-0","volume":"23","author":"T Takeshima","year":"2022","unstructured":"Takeshima T, et al. Early onset of efficacy with fremanezumab in patients with episodic and chronic migraine: subanalysis of two phase 2b\/3 trials in Japanese and Korean patients. J Headache Pain. 2022;23(1):24.","journal-title":"J Headache Pain"},{"issue":"10","key":"1045_CR33","doi-asserted-by":"publisher","first-page":"1743","DOI":"10.1111\/head.13654","volume":"59","author":"PK Winner","year":"2019","unstructured":"Winner PK, et al. Early onset of efficacy with fremanezumab for the preventive treatment of chronic migraine. Headache. 2019;59(10):1743\u201352.","journal-title":"Headache"},{"key":"1045_CR34","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2023.104943","volume":"99","author":"R Ornello","year":"2024","unstructured":"Ornello R, et al. Resistant and refractory migraine: clinical presentation, pathophysiology, and management. EBioMedicine. 2024;99:104943.","journal-title":"EBioMedicine"},{"issue":"5","key":"1045_CR35","doi-asserted-by":"publisher","first-page":"2434","DOI":"10.1007\/s00415-023-12103-4","volume":"271","author":"P Barbanti","year":"2024","unstructured":"Barbanti P, et al. Ultra-late response (> 24 weeks) to anti-CGRP monoclonal antibodies in migraine: a multicenter, prospective, observational study. J Neurol. 2024;271(5):2434\u201343.","journal-title":"J Neurol"},{"issue":"11","key":"1045_CR36","doi-asserted-by":"publisher","first-page":"482","DOI":"10.1212\/WNL.0000000000207292","volume":"101","author":"P Barbanti","year":"2023","unstructured":"Barbanti P, et al. Late response to anti-CGRP monoclonal antibodies in migraine: a multicenter, prospective, observational study. Neurology. 2023;101(11):482\u2013488.","journal-title":"Neurology"},{"issue":"11","key":"1045_CR37","doi-asserted-by":"publisher","first-page":"853","DOI":"10.1177\/0333102414527648","volume":"34","author":"R Burstein","year":"2014","unstructured":"Burstein R, et al. Selective inhibition of meningeal nociceptors by botulinum neurotoxin type A: therapeutic implications for migraine and other pains. Cephalalgia. 2014;34(11):853\u201369.","journal-title":"Cephalalgia"},{"issue":"30","key":"1045_CR38","doi-asserted-by":"publisher","first-page":"7149","DOI":"10.1523\/JNEUROSCI.0576-17.2017","volume":"37","author":"A Melo-Carrillo","year":"2017","unstructured":"Melo-Carrillo A, et al. Selective inhibition of trigeminovascular neurons by fremanezumab: a humanized monoclonal anti-CGRP antibody. J Neurosci. 2017;37(30):7149\u201363.","journal-title":"J Neurosci"},{"issue":"44","key":"1045_CR39","doi-asserted-by":"publisher","first-page":"10587","DOI":"10.1523\/JNEUROSCI.2211-17.2017","volume":"37","author":"A Melo-Carrillo","year":"2017","unstructured":"Melo-Carrillo A, et al. Fremanezumab-A humanized monoclonal anti-CGRP antibody-inhibits thinly myelinated (Adelta) but not unmyelinated (C) meningeal nociceptors. J Neurosci. 2017;37(44):10587\u201396.","journal-title":"J Neurosci"},{"issue":"9","key":"1045_CR40","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1177\/0333102416636843","volume":"36","author":"X Zhang","year":"2016","unstructured":"Zhang X, et al. Extracranial injections of botulinum neurotoxin type A inhibit intracranial meningeal nociceptors\u2019 responses to stimulation of TRPV1 and TRPA1 channels: are we getting closer to solving this puzzle? Cephalalgia. 2016;36(9):875\u201386.","journal-title":"Cephalalgia"},{"issue":"11","key":"1045_CR41","doi-asserted-by":"publisher","first-page":"1358","DOI":"10.1177\/0333102419873675","volume":"39","author":"A Melo-Carrillo","year":"2019","unstructured":"Melo-Carrillo A, et al. Exploring the effects of extracranial injections of botulinum toxin type A on prolonged intracranial meningeal nociceptors responses to cortical spreading depression in female rats. Cephalalgia. 2019;39(11):1358\u201365.","journal-title":"Cephalalgia"},{"issue":"9","key":"1045_CR42","doi-asserted-by":"publisher","first-page":"933","DOI":"10.1177\/03331024221083544","volume":"42","author":"AM Strassman","year":"2022","unstructured":"Strassman AM, et al. Atogepant - an orally-administered CGRP antagonist - attenuates activation of meningeal nociceptors by CSD. Cephalalgia. 2022;42(9):933\u201343.","journal-title":"Cephalalgia"},{"issue":"2","key":"1045_CR43","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1111\/head.14903","volume":"65","author":"M Romozzi","year":"2025","unstructured":"Romozzi M, et al. Pharmacological differences and switching among anti-CGRP monoclonal antibodies: a narrative review. Headache. 2025;65(2):342\u201352.","journal-title":"Headache"},{"issue":"3","key":"1045_CR44","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1097\/WCO.0000000000000932","volume":"34","author":"L Al-Hassany","year":"2021","unstructured":"Al-Hassany L, MaassenVanDenBrink A. Drug interactions and risks associated with the use of triptans, ditans and monoclonal antibodies in migraine. Curr Opin Neurol. 2021;34(3):330\u20138.","journal-title":"Curr Opin Neurol"},{"key":"1045_CR45","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics12121180","author":"D Szkutnik-Fiedler","year":"2020","unstructured":"Szkutnik-Fiedler D. Pharmacokinetics, pharmacodynamics and drug-drug interactions of new anti-migraine drugs-lasmiditan, gepants, and calcitonin-gene-related peptide (CGRP) receptor monoclonal antibodies. Pharmaceutics. 2020. https:\/\/doi.org\/10.3390\/pharmaceutics12121180.","journal-title":"Pharmaceutics"},{"issue":"7","key":"1045_CR46","doi-asserted-by":"publisher","first-page":"1021","DOI":"10.1111\/head.14153","volume":"61","author":"J Ailani","year":"2021","unstructured":"Ailani J, et al. The American Headache Society Consensus Statement: update on integrating new migraine treatments into clinical practice. Headache. 2021;61(7):1021\u201339.","journal-title":"Headache"},{"issue":"4","key":"1045_CR47","doi-asserted-by":"publisher","first-page":"771","DOI":"10.1002\/ana.25831","volume":"88","author":"IA Mulder","year":"2020","unstructured":"Mulder IA, et al. Anti-migraine Calcitonin Gene-Related Peptide Receptor Antagonists worsen cerebral ischemic outcome in mice. Ann Neurol. 2020;88(4):771\u201384.","journal-title":"Ann Neurol"},{"issue":"3","key":"1045_CR48","doi-asserted-by":"publisher","DOI":"10.1177\/03331024231152169","volume":"43","author":"R Messina","year":"2023","unstructured":"Messina R, et al. Safety and tolerability of monoclonal antibodies targeting the CGRP pathway and gepants in migraine prevention: a systematic review and network meta-analysis. Cephalalgia. 2023;43(3):3331024231152169.","journal-title":"Cephalalgia"}],"container-title":["Neurology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40120-026-01045-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40120-026-01045-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40120-026-01045-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T16:48:15Z","timestamp":1791305295000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40120-026-01045-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,6]]},"references-count":48,"alternative-id":["1045"],"URL":"https:\/\/doi.org\/10.1007\/s40120-026-01045-4","relation":{},"ISSN":["2193-8253","2193-6536"],"issn-type":[{"value":"2193-8253","type":"print"},{"value":"2193-6536","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,6]]},"assertion":[{"value":"3 August 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 September 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 October 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Marina Romozzi has received financial support, consulting fees for participation in advisory boards, and support for attending meetings from Lundbeck, Pfizer, and AbbVie. Luigi Francesco Iannone has received financial support, consulting fees for participation in advisory boards, and support for attending meetings from Teva, Eli Lilly, Lundbeck, Pfizer, and AbbVie. He is an Associate Editor for Frontiers in Neurology and a Junior Editor for Cephalalgia and Cephalalgia Reports. Antonio Russo has received speaker honoraria from Allergan, Eli Lilly, AbbVie, Pfizer, Novartis, and Teva and serves as an Associate Editor for the Headache Medicine and Facial Pain section of Frontiers in Neurology. Ian Finkelstein has received grants, honoraria, or consulting fees from Allergan, Amgen, Eli Lilly, Johnson & Johnson, Merck, Purdue, Teva, Aralez, Novartis, Lundbeck, and Pfizer. Dineo Seabi has nothing to disclose. Adam Ahlden has nothing to disclose. Anne Hege Aamodt has received personal fees for lectures or advisory-board participation from Novartis, AbbVie, Teva, Roche, Lundbeck, Pfizer, and Boehringer Ingelheim. She has received non-personal research grants from several sources, including KlinBeForsk, the European Union, Boehringer Ingelheim, Medtronic, and Bristol Myers Squibb. Catello Vollono has received grants, honoraria, or consulting fees from Angelini Pharma, Abbvie, Lundbeck, and Pfizer. Paolo Calabresi has received grants, honoraria, or consulting fees from Amgen, Eli Lilly, Johnson & Johnson, Merck, Teva, Novartis, Lundbeck, and Pfizer. Edoardo Caronna has received honoraria from Novartis, Chiesi, Lundbeck, Medscape, Eli Lilly, Teva, Organon, and Dr. Reddy\u2019s Laboratories. His salary has been partially funded by the R\u00edo Hortega grant, Acci\u00f3n Estrat\u00e9gica en Salud 2017\u20132020, Instituto de Salud Carlos III (CM20\/00217), and by the Juan Rod\u00e9s fellowship, Subprograma Estatal de Incorporaci\u00f3n, Acci\u00f3n Estrat\u00e9gica en Salud 2023 (JR23\/00065). He is a Junior Editor for Cephalalgia. Patricia Pozo-Rosich has received honoraria as a consultant and speaker from AbbVie, Amgen, Dr. Reddy\u2019s Laboratories, Eli Lilly, Lundbeck, Medscape, Novartis, Organon, Pfizer, and Teva Pharmaceuticals during the past three years. Her research group has received research grants from AbbVie, AGAUR, ERA-NET NEURON, FEDER RIS3CAT, Instituto de Salud Carlos III, MICINN, Novartis, and Teva Pharmaceuticals and funding for clinical trials from AbbVie, Amgen, Biohaven, Eli Lilly, Ipsen, Lundbeck, Merz, Novartis, Pfizer, and Teva Pharmaceuticals. She is the founder of\n                      \n                      . Erling Andreas Tronvik has received personal fees for lectures or advisory-board participation from Novartis, Eli Lilly, AbbVie, Teva, Roche, Lundbeck, Pfizer, Biogen, and Organon. He is a consultant for and owns shares and intellectual property in Man & Science, owns shares and intellectual property in Nordic Brain Tech, and owns shares in Keimon Medical. He has received non-personal research grants from several sources, including the Research Council of Norway, KlinBeForsk, and the European Union, and commissioned non-personal research funding from Lundbeck. Christina Sundal has received honoraria for lectures or advisory-board participation from Novartis, AbbVie, Teva, Lundbeck, and Vigil Neuroscience.","order":1,"name":"Ethics","label":"Conflict of Interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The relevant ethics committee approved the data collection on 16 February 2024 (approval number REK 604900). All participants provided written informed consent before study participation. The study was conducted in accordance with the Declaration of Helsinki.","order":2,"name":"Ethics","label":"Ethical Approval","group":{"name":"EthicsHeading","label":"Declarations"}}]}}